DK3325488T3 - Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer - Google Patents
Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer Download PDFInfo
- Publication number
- DK3325488T3 DK3325488T3 DK16828471.9T DK16828471T DK3325488T3 DK 3325488 T3 DK3325488 T3 DK 3325488T3 DK 16828471 T DK16828471 T DK 16828471T DK 3325488 T3 DK3325488 T3 DK 3325488T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- treatment
- chiral diaryl
- macrocycle
- diaryl macrocycle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562195081P | 2015-07-21 | 2015-07-21 | |
US201662302231P | 2016-03-02 | 2016-03-02 | |
PCT/US2016/043132 WO2017015367A1 (en) | 2015-07-21 | 2016-07-20 | Chiral diaryl macrocycles and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3325488T3 true DK3325488T3 (da) | 2020-09-14 |
Family
ID=57834656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16828471.9T DK3325488T3 (da) | 2015-07-21 | 2016-07-20 | Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer |
Country Status (17)
Country | Link |
---|---|
US (3) | US20180325901A1 (da) |
EP (2) | EP3325488B1 (da) |
JP (1) | JP6817287B2 (da) |
KR (1) | KR20180033194A (da) |
CN (1) | CN108026109B (da) |
AU (1) | AU2016296878B2 (da) |
BR (1) | BR112018001065A2 (da) |
CA (1) | CA2992324A1 (da) |
DK (1) | DK3325488T3 (da) |
ES (1) | ES2818528T3 (da) |
HK (1) | HK1254606A1 (da) |
IL (1) | IL256868B (da) |
MX (1) | MX2018000718A (da) |
NZ (1) | NZ738832A (da) |
RU (2) | RU2728579C2 (da) |
WO (1) | WO2017015367A1 (da) |
ZA (1) | ZA201800416B (da) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015112806A2 (en) | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
RU2732405C2 (ru) | 2015-07-02 | 2020-09-16 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ |
LT3319969T (lt) * | 2015-07-06 | 2024-06-10 | Turning Point Therapeutics, Inc. | Diarilo makrociklo polimorfas |
CN108026109B (zh) | 2015-07-21 | 2021-03-02 | 特普医药公司 | 手性二芳基大环及其用途 |
TW201815799A (zh) | 2016-07-28 | 2018-05-01 | 美商Tp生物醫藥公司 | 巨環激酶抑制劑 |
TWI808958B (zh) * | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
CN107267458B (zh) * | 2017-07-06 | 2019-10-29 | 中南大学湘雅二医院 | 一种耐克唑替尼人的非小细胞肺癌细胞株h3122-cr23及其应用 |
SG11202000356VA (en) * | 2017-07-28 | 2020-02-27 | Turning Point Therapeutics Inc | Macrocyclic compounds and uses thereof |
CN109516999B (zh) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
KR102447084B1 (ko) | 2017-11-10 | 2022-09-23 | 앤젝스 파마수티컬, 인크. | Trk 키나제 억제제로서의 거대 고리 화합물 및 그의 용도 |
PT3728271T (pt) | 2017-12-19 | 2022-10-06 | Turning Point Therapeutics Inc | Compostos macrocíclicos para tratar doenças |
BR112020019399A2 (pt) * | 2018-03-28 | 2021-01-05 | Fochon Pharmaceuticals, Ltd. | Compostos macrocíclicos como inibidores de trk quinases |
CN113956269A (zh) * | 2018-04-16 | 2022-01-21 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的二(杂)芳基大环化合物 |
US20220162218A1 (en) * | 2018-04-25 | 2022-05-26 | Primegene (Beijing) Co., Ltd. | Diaryl macrocyclic compound and pharmaceutical composition, and use thereof |
CN111918868B (zh) * | 2018-05-04 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 作为蛋白激酶调节剂的二芳基大环化合物 |
MX2021004538A (es) | 2018-10-22 | 2021-09-10 | Esker Therapeutics Inc | Inhibidores de tyk2 y sus usos. |
CN111171049B (zh) * | 2018-11-09 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂及其用途 |
PE20220135A1 (es) * | 2019-06-19 | 2022-01-27 | Turning Point Therapeutics Inc | Polimorfos de un inhibidor de cinasas macrociclicas |
EP4065395A4 (en) | 2019-11-27 | 2024-02-14 | Turning Point Therapeutics, Inc. | COMBINATION THERAPY WITH DIARYL MACROCYCLIC COMPOUNDS |
CN111689883B (zh) * | 2020-05-22 | 2022-02-11 | 上海应用技术大学 | 一种二芳基砜类化合物的合成方法 |
JP2023528907A (ja) * | 2020-06-04 | 2023-07-06 | シンノハブ ファーマシューティカル カンパニー,リミティド | 大環状構造を有する化合物及びその使用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE195935T1 (de) | 1993-03-25 | 2000-09-15 | Upjohn Co | Formyl- oder cyano- substituierte indolderivate mit dopaminergischer wirkung |
UA44690C2 (uk) * | 1993-12-07 | 2002-03-15 | Елі Ліллі Енд Компані | Макроциклічна сполука іміду біс-індол-малеїнової кислоти, спосіб її одержання та фармацевтична композиція, макроциклічні сполуки іміду біс-індол-малеїнової кислоти та біс-індол-малеїнового ангідриду, спосіб одержання (варіанти) |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
RU2275373C2 (ru) * | 2000-12-08 | 2006-04-27 | Орто-Макнейл Фармасьютикал, Инк. | Макрогетероциклические соединения |
EP2065380A1 (en) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
MX2011002470A (es) * | 2008-09-08 | 2011-04-05 | Merck Patent Gmbh | Pirimidinas macrociclicas como inhibidores de aurora cinasa. |
SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
SG196855A1 (en) | 2008-10-22 | 2014-02-13 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
AU2009308675A1 (en) | 2008-10-31 | 2010-05-06 | Genentech, Inc. | Pyrazolopyrimidine JAK inhibitor compounds and methods |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
BR112012008586A2 (pt) | 2009-10-13 | 2016-11-29 | Elanco Animal Health Ireland | inibidores da integrase macrocíclicos |
SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
PT3205654T (pt) | 2010-05-20 | 2019-04-22 | Array Biopharma Inc | Compostos macrocíclicos como inibidores de cinases trk |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
JP2014524442A (ja) * | 2011-08-19 | 2014-09-22 | メルク・シャープ・アンド・ドーム・コーポレーション | Hcvプロテアーゼ阻害剤の結晶形態 |
DK2760867T3 (da) | 2011-09-30 | 2016-04-11 | Oncodesign Sa | Makrocykliske flt3-kinaseinhibitorer |
CN104169286B (zh) | 2012-03-06 | 2016-06-08 | 辉瑞大药厂 | 用于治疗增殖性疾病的大环衍生物 |
KR101965025B1 (ko) | 2012-03-09 | 2019-04-02 | 렉시컨 파마슈티컬스 인코퍼레이티드 | 피라졸로[1,5-a]피리미딘계 화합물, 그를 포함하는 조성물 및 그의 사용 방법 |
MX347917B (es) * | 2012-03-09 | 2017-05-17 | Lexicon Pharmaceuticals Inc | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. |
GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
WO2015112806A2 (en) | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
RU2732405C2 (ru) | 2015-07-02 | 2020-09-16 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ |
LT3319969T (lt) * | 2015-07-06 | 2024-06-10 | Turning Point Therapeutics, Inc. | Diarilo makrociklo polimorfas |
CN108026109B (zh) | 2015-07-21 | 2021-03-02 | 特普医药公司 | 手性二芳基大环及其用途 |
TW201815799A (zh) | 2016-07-28 | 2018-05-01 | 美商Tp生物醫藥公司 | 巨環激酶抑制劑 |
TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
SG11202000356VA (en) | 2017-07-28 | 2020-02-27 | Turning Point Therapeutics Inc | Macrocyclic compounds and uses thereof |
-
2016
- 2016-07-20 CN CN201680052319.6A patent/CN108026109B/zh active Active
- 2016-07-20 WO PCT/US2016/043132 patent/WO2017015367A1/en active Application Filing
- 2016-07-20 MX MX2018000718A patent/MX2018000718A/es unknown
- 2016-07-20 DK DK16828471.9T patent/DK3325488T3/da active
- 2016-07-20 EP EP16828471.9A patent/EP3325488B1/en active Active
- 2016-07-20 ES ES16828471T patent/ES2818528T3/es active Active
- 2016-07-20 US US15/745,915 patent/US20180325901A1/en not_active Abandoned
- 2016-07-20 NZ NZ738832A patent/NZ738832A/en unknown
- 2016-07-20 RU RU2018106245A patent/RU2728579C2/ru active
- 2016-07-20 KR KR1020187002289A patent/KR20180033194A/ko not_active Application Discontinuation
- 2016-07-20 EP EP20181616.2A patent/EP3733187B1/en active Active
- 2016-07-20 CA CA2992324A patent/CA2992324A1/en active Pending
- 2016-07-20 AU AU2016296878A patent/AU2016296878B2/en active Active
- 2016-07-20 JP JP2018502668A patent/JP6817287B2/ja active Active
- 2016-07-20 RU RU2020123800A patent/RU2020123800A/ru unknown
- 2016-07-20 BR BR112018001065-0A patent/BR112018001065A2/pt not_active Application Discontinuation
-
2018
- 2018-01-11 IL IL256868A patent/IL256868B/en active IP Right Grant
- 2018-01-19 ZA ZA2018/00416A patent/ZA201800416B/en unknown
- 2018-10-23 HK HK18113572.9A patent/HK1254606A1/zh unknown
-
2020
- 2020-08-20 US US16/998,763 patent/US11452725B2/en active Active
-
2022
- 2022-08-15 US US17/819,858 patent/US20230346786A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2018000718A (es) | 2020-01-20 |
KR20180033194A (ko) | 2018-04-02 |
US20230346786A1 (en) | 2023-11-02 |
CN108026109A (zh) | 2018-05-11 |
HK1254606A1 (zh) | 2019-07-26 |
CN108026109B (zh) | 2021-03-02 |
RU2018106245A (ru) | 2019-08-21 |
WO2017015367A1 (en) | 2017-01-26 |
EP3325488A4 (en) | 2019-04-24 |
US20180325901A1 (en) | 2018-11-15 |
AU2016296878A1 (en) | 2018-01-25 |
JP6817287B2 (ja) | 2021-01-20 |
RU2018106245A3 (da) | 2019-12-26 |
EP3325488A1 (en) | 2018-05-30 |
EP3733187A1 (en) | 2020-11-04 |
IL256868A (en) | 2018-03-29 |
ES2818528T3 (es) | 2021-04-13 |
RU2728579C2 (ru) | 2020-07-30 |
BR112018001065A2 (pt) | 2018-09-11 |
AU2016296878B2 (en) | 2020-12-17 |
US20210030756A1 (en) | 2021-02-04 |
US11452725B2 (en) | 2022-09-27 |
CA2992324A1 (en) | 2017-01-26 |
EP3325488B1 (en) | 2020-06-24 |
RU2020123800A (ru) | 2020-10-02 |
JP2018524382A (ja) | 2018-08-30 |
IL256868B (en) | 2021-03-25 |
EP3733187B1 (en) | 2024-10-16 |
ZA201800416B (en) | 2021-07-28 |
NZ738832A (en) | 2024-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3325488T3 (da) | Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer | |
DK3678668T3 (da) | ENPP1-inhibitorer og deres anvendelse til behandling af kræft | |
ZA201904695B (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
DK3612517T3 (da) | Bicykliske forbindelser og deres anvendelse ved behandling af cancer | |
DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
DK3285809T3 (da) | Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. | |
DK3416957T3 (da) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
DK3371152T3 (da) | Sammensætninger omfattende en hæmmer af lysinspecifik demethylase-1 med en pyrimidinring og anvendelse deraf i behandling af cancer | |
DK3439663T3 (da) | Fremgangsmåder til behandling af pædiatriske cancere | |
DK3076972T3 (da) | Cancerbehandling med kombination af plinabulin og taxan | |
DK3227237T3 (da) | Indretning og anvendelse deraf til uv-bearbejdning af fluider | |
DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
DK3416945T3 (da) | 6-aryl-4-(morpholin-4-yl)-1h-pyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
DK3374497T3 (da) | Modificerede makrofager til anvendelse i behandlingen af kræft | |
DK3532067T3 (da) | Liposomal formulering til anvendelse til behandling af cancer | |
DK3174559T3 (da) | Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer | |
DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
DK3790879T3 (da) | Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft | |
GB201514021D0 (en) | Novel Pyridines and their use in the treatment of cancer | |
DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer | |
DK3258964T3 (da) | Detektion og behandling af maligne tumorer i CNS | |
DK3383872T3 (da) | 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling | |
DK3442558T3 (da) | Bmp-7-afledte peptider til anvendelse i behandlingen af osteoartritis |